GleamWall
中文EN

CDT CDT Equity Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1896212 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-70.5%
TTM EPS YoY199.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-49.2%
ROA-41.4%
ROIC (approx.)-37.1%
Asset turnover—

Leverage & solvency

Liabilities / assets14.1%
Debt / equity0.00x
Current ratio0.20x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.29x
Accruals ratio-29.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$563,000$302,000$778,000$746,000$1.53M$1.86M$916,000$132,000
SG&A expense$3.33M$2.70M$2.88M$20.41M$5.50M$3.09M$2.70M$3.38M
Operating income-$3.90M-$3.00M-$3.66M-$21.16M-$7.03M-$4.95M-$3.62M-$3.51M
Interest expense———$0$100,000$100,000$100,000-$97,000
Net income-$4.58M-$4.64M-$4.06M-$21.32M-$7.12M-$6.03M-$4.75M-$2.41M
EPS (basic)-288.89-8.71-5.56—-1,779,500.00-10,940.11-3,670.27—
EPS (diluted)-288.89-8.71-5.56—-1,779,500.00-10,940.11-3,670.27—
Weighted avg. shares (diluted)15,864532,999730,461—45511,295—
Balance sheet
Cash & equivalents$1.72M$747,000$97,000$1.51M$3.84M$3.33M$2.13M$554,000
Short-term investments——————$600,000$600,000
Current assets$4.39M$2.94M$3.05M$4.38M$7.09M$6.39M$5.95M$2.71M
PP&E, net$102,000$158,000$213,000$269,000$325,000$381,000$434,000$40,000
Intangibles——————$400,000—
Total assets$158.73M$126.71M$127.09M$5.65M$8.55M$7.99M$7.71M$4.19M
Current liabilities$22.15M$23.35M$21.64M$12.82M$4.26M$4.41M$4.55M$10.74M
Total liabilities$22.33M$23.61M$21.64M$12.82M$4.27M$4.46M$4.63M$10.99M
Shareholders' equity$136.39M$103.09M$105.45M-$7.17M$4.28M$3.53M$3.08M-$6.79M
Shares outstanding73,866631,0804.72M181.28M2.39M9.51M461
Cash flow statement
Operating cash flow-$2.88M-$544,000-$1.89M-$4.64M-$4.41M-$2.18M-$3.93M-$3.81M
Capital expenditure————-$7,000$401,000$404,000$0
Free cash flow————-$4.40M-$2.58M-$4.33M-$3.81M
Investing cash flow———$595,000-$998,000-$401,000-$404,000$85,000
Financing cash flow$4.00M$1.19M$487,000$1.74M$6.00M$3.76M$5.93M$4.21M
Stock-based compensation$199,000$200,000$198,000$211,000$1.58M$160,000$234,000$362,000

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.